HK1217101A1 - 取代的恶唑烷酮类的醛衍生物 - Google Patents

取代的恶唑烷酮类的醛衍生物 Download PDF

Info

Publication number
HK1217101A1
HK1217101A1 HK16105076.8A HK16105076A HK1217101A1 HK 1217101 A1 HK1217101 A1 HK 1217101A1 HK 16105076 A HK16105076 A HK 16105076A HK 1217101 A1 HK1217101 A1 HK 1217101A1
Authority
HK
Hong Kong
Prior art keywords
formula
compound
rivaroxaban
oxo
phenyl
Prior art date
Application number
HK16105076.8A
Other languages
English (en)
Chinese (zh)
Inventor
．尼廷
S．P．尼廷
．尼勒什
S．P．尼勒什
．拉杰什
R．W．拉杰什
S．K．尼勒什
．珊迪珀
B．P．珊迪珀
．塔拉克
S．P．塔拉克
Original Assignee
Wanbury有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wanbury有限公司 filed Critical Wanbury有限公司
Publication of HK1217101A1 publication Critical patent/HK1217101A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK16105076.8A 2012-12-26 2013-12-24 取代的恶唑烷酮类的醛衍生物 HK1217101A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3359/MUM/2012 2012-12-26
PCT/IN2013/000801 WO2014102822A2 (en) 2012-12-26 2013-12-24 Aldehyde derivative of substitute oxazolidinones
IN3359MU2012 IN2012MU03359A (cg-RX-API-DMAC7.html) 2012-12-26 2013-12-24

Publications (1)

Publication Number Publication Date
HK1217101A1 true HK1217101A1 (zh) 2016-12-23

Family

ID=54242230

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105076.8A HK1217101A1 (zh) 2012-12-26 2013-12-24 取代的恶唑烷酮类的醛衍生物

Country Status (15)

Country Link
US (1) US9359341B2 (cg-RX-API-DMAC7.html)
EP (1) EP2897619A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016504348A (cg-RX-API-DMAC7.html)
KR (1) KR20150100661A (cg-RX-API-DMAC7.html)
CN (1) CN105431429A (cg-RX-API-DMAC7.html)
AU (1) AU2013368847B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015011033A2 (cg-RX-API-DMAC7.html)
CA (1) CA2883323A1 (cg-RX-API-DMAC7.html)
HK (1) HK1217101A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012MU03359A (cg-RX-API-DMAC7.html)
MX (1) MX2015003319A (cg-RX-API-DMAC7.html)
PH (1) PH12015501625A1 (cg-RX-API-DMAC7.html)
RU (1) RU2015112195A (cg-RX-API-DMAC7.html)
WO (1) WO2014102822A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201503700B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20161588T1 (hr) 2012-12-26 2017-01-13 Wanbury Limited Intermedijer rivaroksabana i njegova priprava
US20160251342A1 (en) * 2012-12-26 2016-09-01 Wanbury Ltd. Aldehyde derivative of substituted oxazolidinones

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
GT200600196A (es) 2005-05-23 2007-01-15 Compuestos n-formil de hidroxilamina
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102006007146A1 (de) * 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
JP5389028B2 (ja) 2007-08-14 2014-01-15 コンサート ファーマシューティカルズ インコーポレイテッド 置換オキサゾリジノン誘導体
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
EP2459555B1 (en) 2009-07-31 2021-11-03 KRKA, D.D., Novo Mesto Processes for crystallization of rivaroxaban
US20120283434A1 (en) 2010-01-04 2012-11-08 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
EA201370107A1 (ru) * 2010-11-11 2013-11-29 Редкс Фарма Лимитед Производные лекарственных средств
WO2012140061A1 (en) 2011-04-11 2012-10-18 Sandoz Ag Method for the preparation of substituted oxazolidinones
GEP20156397B (en) 2011-05-06 2015-11-10 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Process for the preparation of a rivaroxaban and intermediates formed in said process
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
HRP20161588T1 (hr) 2012-12-26 2017-01-13 Wanbury Limited Intermedijer rivaroksabana i njegova priprava

Also Published As

Publication number Publication date
MX2015003319A (es) 2015-08-14
CN105431429A (zh) 2016-03-23
IN2012MU03359A (cg-RX-API-DMAC7.html) 2015-06-26
US9359341B2 (en) 2016-06-07
EP2897619A2 (en) 2015-07-29
KR20150100661A (ko) 2015-09-02
EP2897619A4 (en) 2016-08-17
RU2015112195A (ru) 2017-01-31
CA2883323A1 (en) 2014-07-03
ZA201503700B (en) 2016-10-26
AU2013368847B2 (en) 2017-03-16
BR112015011033A2 (pt) 2017-07-11
WO2014102822A2 (en) 2014-07-03
US20150259333A1 (en) 2015-09-17
WO2014102822A3 (en) 2015-10-29
PH12015501625A1 (en) 2015-09-28
AU2013368847A1 (en) 2015-05-28
JP2016504348A (ja) 2016-02-12

Similar Documents

Publication Publication Date Title
ES2605388T3 (es) Compuesto inhibidor de Trk
Polucci et al. Alkylsulfanyl-1, 2, 4-triazoles, a new class of allosteric valosine containing protein inhibitors. Synthesis and structure–activity relationships
JP5575646B2 (ja) ４−（４−ピリジニル）−ベンズアミドおよびｒｏｃｋ活性調節因子としてのこれらの使用
AU2014239677B2 (en) Histone deacetylase inhibitors
Kennedy et al. Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells
JP5484726B2 (ja) Ｇｓｋ−３阻害剤
HUT74103A (en) Aroyl-piperidine derivative
JP4624982B2 (ja) 血栓症の処置のための凝固因子Ｘａ阻害剤としての１−Ｎ−（フェニル）−２−Ｎ−（フェニル）ピラゾリジン−１，２−ジカルボキサミド誘導体
WO2014003153A1 (ja) 置換アミド化合物
CA2623294C (en) 2-aminoethoxyacetic acid derivatives and their use
JP2022514303A (ja) 置換されているオキソピリジン誘導体
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
CN111093658A (zh) 用于治疗皮肤疾病的稠合杂芳环-苯胺化合物
Xu et al. Discovery of potent and orally bioavailable pyridine N-oxide-based factor XIa inhibitors through exploiting nonclassical interactions
CA3250650A1 (en) ARYLBENZOISOXAZOLE COMPOUNDS USED AS IP6K AND IPMK INHIBITORS AND THEIR METHODS OF USE
HK1217101A1 (zh) 取代的恶唑烷酮类的醛衍生物
JP7118347B2 (ja) 重水素化（ｓ）２－（４－（ピペリジン－３－イル）フェニル）－２ｈ－インダゾール－７－カルボキサミド
WO1998027061A1 (en) N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivatives
TW200829568A (en) Quinolone derivative or pharmaceutically acceptable salt thereof
CN118221610A (zh) 一种苯基噻唑胺类PI4KIIIβ/HDAC双靶抑制剂、制备方法及其药物组合物和应用
CN114206868B (zh) 作为hdac6抑制剂的3-(2-(杂芳基)-吡啶-4-基)-5-(三氟甲基)-1,2,4-噁二唑衍生物
US20160251342A1 (en) Aldehyde derivative of substituted oxazolidinones
EP3792252A1 (en) Thiazole and diphenyl substituted sulfoxides for use in improving cognition functions and against addictions to substances.
WO2015037747A1 (en) Anticancer agent comprising aminoacetonitrile compound as active ingredient
Naithani et al. Kaushal Naithani1, Arka Das1, Mamta Ushare1, Subham Nath1, 2, Rashmita Biswas1, 2, Anirban Kundu3, Kazi Tawsif Ahmed4, Utpal Mohan1, 2 and Subhendu Bhowmik1